EHC: Recognizing Von Willebrand Factor as a Critical Medicine in Bleeding Care
The European Haemophilia Consortium (EHC) recently shared a post on X:
”Von Willebrand Disease affects 1:1000 individuals and, if not recognised, may cause severe bleeding symptoms after trauma or surgery that can be life-threatening. It’s time for health systems to recognise Von Willebrand Factor as a Critical Medicine. European Medicines Agency”
Von Willebrand Disease (VWD), the most common inherited bleeding disorder, affects approximately 1 in 1,000 individuals.
When unrecognized or untreated, it can lead to serious, even life-threatening bleeding, particularly after trauma or surgical procedures.
Despite its prevalence and potential severity, VWD remains underdiagnosed and undertreated in many health systems.
There is an urgent need to designate Von Willebrand Factor (VWF) as a Critical Medicine to ensure timely diagnosis, treatment access, and improved outcomes for patients.
Recognizing VWF’s essential role in bleeding management is a key step toward better care for individuals living with VWD worldwide.
Hemostasis Today, your daily update on the waves in bleeding disorders community.
-
Jul 11, 2025, 19:14ISTH 2025 for Cardiac Surgery: LEX-211 (FARES-II) Trial Shows Promising Results
-
Jul 11, 2025, 16:48GPAS 2025: Shaping the Future of Bleeding Disorder Care
-
Jul 10, 2025, 11:23HTRS Thanks CSL Behring for Its Ongoing Commitment to Research Support
-
Jul 9, 2025, 14:11Join Dr. Bethany Samuelson Bannow for a Virtual Event on Hemostasis and Cancer
-
Jul 9, 2025, 13:59Late-Breaking Insights from ISTH 2025: Rurioctocog Alfa Pegol in PUPs with Hemophilia A
-
Jul 12, 2025, 15:337 Tesla MRI Sheds Light on END Mechanisms in Symptomatic MCA Stenosis
-
Jul 12, 2025, 15:221 in 100: Subclavian Steal Syndrome Revealed by LVO Stroke in Case with Persistent Trigeminal Artery
-
Jul 11, 2025, 18:50ICAS Not a Factor: Post-EVT Intensive BP Control within 24 hrs Worsens Outcomes
-
Jul 11, 2025, 17:57Need for Recanalization Strategies Reinforced in P1 and P2: PCA Stroke Poor Outcomes
-
Jul 11, 2025, 15:40Wolfgang Miesbach: How to Better Understand and Explain Gene Therapy of Haemophilia?
-
Jul 7, 2025, 17:08Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
-
Jul 6, 2025, 21:00From Untouchable to Editable: How 21st-Century Gene Editing Breakthroughs Clash with Systemic Barriers
-
Mar 6, 2025, 17:15Olympus Announces Launch of Single-Use Hemostasis Clip
-
Jul 10, 2025, 18:25Dr. Carol Kasper: Honoring the Legacy
-
Jul 8, 2025, 08:26ASH and HVO Collaborate to Expand Hematology Training in LMICs
-
Jul 6, 2025, 15:02Patients as Experts: EHC Calls for Early Involvement in HTA Systems
-
Jul 6, 2025, 14:56Missed ISTH 2025? Congress Daily Has You Covered
-
Jul 6, 2025, 11:48Japan's Youth Engagement in Hemophilia Care: Where Even the Doctors Get It – HABIT Summit 2025